APR-246 increases tumor antigenicity independent of p53.

Mice Animals CD8-Positive T-Lymphocytes Tumor Suppressor Protein p53 / genetics Antigens, Neoplasm Melanoma

Journal

Life science alliance
ISSN: 2575-1077
Titre abrégé: Life Sci Alliance
Pays: United States
ID NLM: 101728869

Informations de publication

Date de publication:
01 2024
Historique:
received: 18 02 2023
revised: 17 10 2023
accepted: 19 10 2023
medline: 30 10 2023
pubmed: 28 10 2023
entrez: 27 10 2023
Statut: epublish

Résumé

We previously reported that activation of p53 by APR-246 reprograms tumor-associated macrophages to overcome immune checkpoint blockade resistance. Here, we demonstrate that APR-246 and its active moiety, methylene quinuclidinone (MQ) can enhance the immunogenicity of tumor cells directly. MQ treatment of murine B16F10 melanoma cells promoted activation of melanoma-specific CD8

Identifiants

DOI: 10.26508/lsa.202301999 PMID: 37891002 PMC: PMC10610029
pubmed: 37891002
pii: 7/1/e202301999
doi: 10.26508/lsa.202301999
pmc: PMC10610029
pii:
doi:

Substances chimiques

Tumor Suppressor Protein p53 0
Antigens, Neoplasm 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2023 Michels et al.

Références

Mol Cancer. 2021 Jan 6;20(1):10
pubmed: 33407548
J Exp Med. 1999 Jun 7;189(11):1757-64
pubmed: 10359579
N Engl J Med. 2016 Nov 10;375(19):1823-1833
pubmed: 27718847
Nature. 2016 Jun 15;534(7608):570-4
pubmed: 27309814
Lancet Oncol. 2021 Apr;22(4):512-524
pubmed: 33721562
Nat Rev Drug Discov. 2011 Mar;10(3):221-37
pubmed: 21358741
Nat Rev Cancer. 2021 Feb;21(2):71-88
pubmed: 33214692
Nat Rev Clin Oncol. 2018 May;15(5):325-340
pubmed: 29508855
Nature. 2020 Sep;585(7823):107-112
pubmed: 32728218
J Clin Invest. 2022 Sep 15;132(18):
pubmed: 36106631
Cell Oncol. 2008;30(5):411-8
pubmed: 18791272
Curr Opin Chem Biol. 2019 Jun;50:29-36
pubmed: 30897495
J Immunother. 2000 Jan;23(1):17-27
pubmed: 10687134
JAMA Dermatol. 2016 Jan;152(1):45-51
pubmed: 26501224
J Biol Chem. 2012 Feb 10;287(7):4419-25
pubmed: 22157013
Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3539-43
pubmed: 8097319
Nat Commun. 2018 Apr 20;9(1):1581
pubmed: 29679077
Cancer Immun. 2009 Jun 05;9:5
pubmed: 19496531
J Exp Med. 2001 Aug 20;194(4):481-9
pubmed: 11514604
Science. 2011 Dec 16;334(6062):1573-7
pubmed: 22174255
Cell Rep. 2019 Apr 16;27(3):806-819.e5
pubmed: 30995478
Cell Death Dis. 2015 Jun 18;6:e1794
pubmed: 26086967
Science. 2012 Sep 28;337(6102):1678-84
pubmed: 23019653
J Exp Med. 1999 Aug 2;190(3):355-66
pubmed: 10430624
Innate Immun. 2015 Aug;21(6):565-74
pubmed: 25540284
J Immunother Emphasis Tumor Immunol. 1996 Jan;19(1):81-4
pubmed: 8859727
Ann Oncol. 2021 May;32(5):661-672
pubmed: 33736924
Nat Commun. 2019 Apr 23;10(1):1899
pubmed: 31015397
Cancer Cell. 2021 Mar 8;39(3):394-406.e4
pubmed: 33482123
N Engl J Med. 2021 Nov 11;385(20):1856-1867
pubmed: 34534429
J Exp Med. 2009 Apr 13;206(4):849-66
pubmed: 19332877
Nat Commun. 2021 Dec 3;12(1):7057
pubmed: 34862374
Sci Rep. 2021 Feb 24;11(1):4480
pubmed: 33627789
N Engl J Med. 2022 Feb 3;386(5):437-448
pubmed: 35045221
Nat Rev Clin Oncol. 2020 Jul;17(7):418-434
pubmed: 32242094
Nat Commun. 2017 Mar 28;8:14844
pubmed: 28348409
ESMO Open. 2022 Oct;7(5):100573
pubmed: 36084396
Lancet. 2019 Nov 23;394(10212):1915-1928
pubmed: 31679945
Cell Death Dis. 2013 Oct 24;4:e881
pubmed: 24157875
J Immunol. 2009 Nov 15;183(10):6186-97
pubmed: 19864596
N Engl J Med. 2019 Oct 17;381(16):1535-1546
pubmed: 31562797
N Engl J Med. 2019 Jan 3;380(1):45-56
pubmed: 30501490
Cancer Res. 2006 May 1;66(9):4904-12
pubmed: 16651447
Immunity. 1997 Mar;6(3):273-81
pubmed: 9075928
Cancer Cell. 2011 Mar 8;19(3):387-400
pubmed: 21397861
J Exp Med. 2003 Aug 18;198(4):569-80
pubmed: 12925674
N Engl J Med. 2018 May 31;378(22):2078-2092
pubmed: 29658856
Free Radic Biol Med. 2015 Mar;80:148-57
pubmed: 25433365
Cancer Cell. 2009 May 5;15(5):376-88
pubmed: 19411067
Lancet Oncol. 2020 Dec;21(12):1563-1573
pubmed: 33284113
Nat Methods. 2009 May;6(5):359-62
pubmed: 19377485
Clin Cancer Res. 2018 Feb 1;24(3):592-599
pubmed: 28954788
J Exp Med. 1998 Jul 20;188(2):277-86
pubmed: 9670040
Nat Rev Cancer. 2020 Nov;20(11):662-680
pubmed: 32753728
Anal Biochem. 2008 Apr 15;375(2):187-95
pubmed: 18162165
Nat Rev Clin Oncol. 2022 Jul;19(7):441-457
pubmed: 35365796
J Immunol. 2002 Jan 15;168(2):926-32
pubmed: 11777991
Lancet Oncol. 2019 Oct;20(10):1370-1385
pubmed: 31427204
Sci Rep. 2018 Aug 23;8(1):12671
pubmed: 30140002
Nat Commun. 2019 Jul 26;10(1):3349
pubmed: 31350406
J Clin Oncol. 2015 May 10;33(14):1543-50
pubmed: 25823737
Nat Metab. 2020 Apr;2(4):318-334
pubmed: 32691018
J Exp Med. 2004 Sep 20;200(6):771-82
pubmed: 15381730
J Clin Invest. 2019 Jul 22;129(8):3435-3447
pubmed: 31329159

Auteurs

Judith Michels (J)

https://ror.org/02r109517 Department of Pharmacology, Swim Across America and Ludwig Collaborative Laboratory, Weill Cornell Medicine, New York, NY, USA.
https://ror.org/02r109517 Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA.
ORCID: 0000-0002-9640-0222

Divya Venkatesh (D)

https://ror.org/02r109517 Department of Pharmacology, Swim Across America and Ludwig Collaborative Laboratory, Weill Cornell Medicine, New York, NY, USA.
https://ror.org/02r109517 Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA.

Cailian Liu (C)

https://ror.org/02r109517 Department of Pharmacology, Swim Across America and Ludwig Collaborative Laboratory, Weill Cornell Medicine, New York, NY, USA.
https://ror.org/02r109517 Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA.

Sadna Budhu (S)

https://ror.org/02r109517 Department of Pharmacology, Swim Across America and Ludwig Collaborative Laboratory, Weill Cornell Medicine, New York, NY, USA.
https://ror.org/02r109517 Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA.

Hong Zhong (H)

https://ror.org/02r109517 Department of Pharmacology, Swim Across America and Ludwig Collaborative Laboratory, Weill Cornell Medicine, New York, NY, USA.
https://ror.org/02r109517 Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA.

Mariam M George (MM)

https://ror.org/02r109517 Department of Pharmacology, Swim Across America and Ludwig Collaborative Laboratory, Weill Cornell Medicine, New York, NY, USA.
https://ror.org/02r109517 Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA.

Daniel Thach (D)

https://ror.org/02r109517 Department of Pharmacology, Swim Across America and Ludwig Collaborative Laboratory, Weill Cornell Medicine, New York, NY, USA.
https://ror.org/02r109517 Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA.
ORCID: 0000-0002-7609-8775

Zhong-Ke Yao (ZK)

The Organic Synthesis Core Facility, MSK, New York, NY, USA.
ORCID: 0000-0002-0427-686X

Ouathek Ouerfelli (O)

The Organic Synthesis Core Facility, MSK, New York, NY, USA.
ORCID: 0000-0002-7038-0219

Hengrui Liu (H)

Department of Biological Sciences, Columbia University, New York, NY, USA.
ORCID: 0000-0002-5214-1572

Brent R Stockwell (BR)

Department of Biological Sciences, Columbia University, New York, NY, USA.
Department of Chemistry, Columbia University, New York, NY, USA.

Luis Felipe Campesato (LF)

https://ror.org/02r109517 Department of Pharmacology, Swim Across America and Ludwig Collaborative Laboratory, Weill Cornell Medicine, New York, NY, USA.
https://ror.org/02r109517 Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA.

Dmitriy Zamarin (D)

Swim Across America and Ludwig Collaborative Laboratory, Immunology Program, Parker Institute for Cancer Immunotherapy, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Immuno-Oncology Service, Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Roberta Zappasodi (R)

Department of Medicine, Weill Cornell, New York, NY, USA.
ORCID: 0000-0002-7031-6671

Jedd D Wolchok (JD)

https://ror.org/02r109517 Department of Pharmacology, Swim Across America and Ludwig Collaborative Laboratory, Weill Cornell Medicine, New York, NY, USA jwolchok@med.cornell.edu.
https://ror.org/02r109517 Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA.
Department of Medicine, Weill Cornell, New York, NY, USA.
ORCID: 0000-0001-6718-2222

Taha Merghoub (T)

https://ror.org/02r109517 Department of Pharmacology, Swim Across America and Ludwig Collaborative Laboratory, Weill Cornell Medicine, New York, NY, USA tmerghoub@med.cornell.edu.
https://ror.org/02r109517 Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, NY, USA.
Department of Medicine, Weill Cornell, New York, NY, USA.
ORCID: 0000-0002-1518-5111

Articles similaires

Evaluating the efficacy of telesurgery with dual console SSI Mantra Surgical Robotic System: experiment on animal model and clinical trials.

Sudhir Prem Srivastava, Vishwajyoti Pascual Srivastava, Avinesh Singh et al.
1.00
Robotic Surgical Procedures Animals Humans Telemedicine Models, Animal

Odour generalisation and detection dog training.

Lyn Caldicott, Thomas W Pike, Helen E Zulch et al.
1.00
Animals Odorants Dogs Generalization, Psychological Smell

FBXO22 inhibits colitis and colorectal carcinogenesis by regulating the degradation of the S2448-phosphorylated form of mTOR.

Minle Li, Xuan Chen, Pengfei Qu et al.
1.00
Animals TOR Serine-Threonine Kinases Colorectal Neoplasms Colitis Mice

Use of organic material provided by an automatic enrichment device by weaner pigs and its influence on tail lesions.

Philipp Heseker, Jeanette Probst, Stefanie Ammer et al.
1.00
Animals Tail Swine Behavior, Animal Animal Husbandry

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › APR-246 increases tumor antigenicity...
questionsmedicales.fr › Eucaryotes › Animaux › APR-246 increases tumor antigenicity...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Lymphocytes T › Lymphocytes T CD8+ › APR-246 increases tumor antigenicity...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Phosphoprotéines › Protéine p53 suppresseur de tumeur › APR-246 increases tumor antigenicity...
questionsmedicales.fr › Facteurs biologiques › Antigènes › Antigènes néoplasiques › APR-246 increases tumor antigenicity...
questionsmedicales.fr › Tumeurs › Tumeurs par type histologique › Naevus et mélanomes › Mélanome › APR-246 increases tumor antigenicity...